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a b s t r a c t
Aims: We evaluated the associations of diabetic complications and underlying pathology
with daily walking activity in type 2 diabetic patients without manifest mobility limitations.
Methods: 100 persons with type 2 diabetes (mean age 64.5  9.4 years) were studied. Persons
with manifest mobility limitations were excluded. Possible determinants measured: pe-
ripheral neuropathy, neuropathic pain, peripheral arterial disease, cardiovascular disease,
decreased muscle strength (handgrip strength), BMI, depression, falls and fear of falling.
Walking activity was measured during one week with a pedometer. Functional capacity was
measured with the 6 min walk test, the timed ‘‘up and go’’ test and a stair climbing test.
Results: Prevalence of neuropathy (40%) and obesity (53%) was high. Persons took a median
of 6429 steps/day. In multivariate regression analysis, adjusted for age and sex, neuropathy
was associated with a reduction of 1967 steps/day, decreased muscle strength with 1782
steps/day, and an increase in BMI of 1 kg/m2 with a decrease of 210 steps/day (all
p < 0.05). Decreased muscle strength and BMI, but not neuropathy, were associated with
outcome of functional capacity tests in multiple regression analysis.
Conclusions: Peripheral neuropathy, decreased muscle strength and obesity are strongly
associated with walking in persons with type 2 diabetes without manifest mobility
limitations.
# 2010 Elsevier Ireland Ltd. All rights reserved.
C o n te n t s l i s t s a v a i l a b l e a t S c i en c e D i r e c t
Diabetes Research
and Clinical Practice
journal homepage: www.elsevier .com/locate/diabres1. Introduction
International guidelines state that physical exercise is one of
the cornerstones in the treatment of type 2 diabetes mellitus
[1]. It has been shown that physical exercise improves
glycemic control, lowers blood pressure, improves lipid
profile, decreases abdominal fat mass and lowers both
cardiovascular morbidity and mortality [1,2]. Unfortunately,§ Presented on annual meeting of the Diabetic Foot Study Group 20
* Corresponding author at: Dept. of Medicine, Maastricht University M
The Netherlands. Tel.: +31 06 21214590; fax: +31 043 3875006.
E-mail address: t.vansloten@student.maastrichtuniversity.nl (T.T.
0168-8227/$ – see front matter # 2010 Elsevier Ireland Ltd. All rights
doi:10.1016/j.diabres.2010.09.030only 30–40% of persons with type 2 diabetes meet the goals for
daily physical activity and long term adherence to supervised
exercise programs is generally poor [3].
The failure to increase physical activity in type 2 diabetes
has been explained by sociodemographic, motivational and
environmental factors. An additional explanation for the
relatively poor physical activity in persons with type 2 diabetes
could be that the underlying pathology of diabetes (i.e. obesity)
and the presence of diabetic complications have negative09, Bled, Slovenia at 26th of September 2009.
edical Centre, P. Debyelaan 25, P.O. Box 5800, 6202 AZ Maastricht,
van Sloten).
reserved.
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However, the relationship between these disorders and
physical activity has received only little attention.
Studies are needed which investigate whether diabetic
complications and underlying pathology affect physical
activity in persons with type 2 diabetes without manifest
mobility limitations. In most supervised diabetic exercise
programs, persons are excluded when they have major
diabetic complications or severe chronic diseases, such as
severe cardiac disease or severe arthritis, as these disorders
have a great impact on mobility. However, diabetic partici-
pants included in exercise programs may have clinically less
severe or clinically less manifest disorders, such as peripheral
neuropathy and mild peripheral arterial disease. Most exercise
programs do not take such disorders into account, even
though these complications could also negatively affect
physical activity and adherence to intervention studies. For
example, a recently performed brisk walking exercise study by
Praet and van Loon [5] had a high dropout rate of 60%.
Although persons with cardiac disease, peripheral arterial
disease, orthopaedic limitations or diabetic foot ulcerations
were excluded, the high dropout rate might for a large part be
explained by underlying physical limitations among partici-
pants.
In this study, daily walking activity is measured. Previous
research showed that walking is the physical activity most
frequently engaged by persons with type 2 diabetes [2]. In
addition, walking is an important physical activity as it is
directly related to all-cause and CVD mortality [2].
The aim of this study is to investigate the association of
diabetic complications and underlying pathology with daily
walking activity in persons with type 2 diabetes without
manifest mobility limitations. We hypothesise that in these
persons diabetic complications and underlying pathologies
negatively affect walking activity.
2. Subjects, materials and methods
2.1. Study design and subjects
The study was performed in the region of Maastricht, the
Netherlands. The majority of diabetic patients (90%) in this
region is treated by general practitioners (GP’s). Participants
were recruited from ten randomly selected general practices
between September 2007 and February 2008 (these represent
late summer to winter months in the Netherlands). From these
practices, a random sample was chosen of 400 patients with
type 2 diabetes (age  40 years). In this sample, we selected
persons without major diabetic complications and without
manifest mobility limitations. The selection process was
performed by the main investigator (TVS), with assistance
of the GP’s, using electronic patient records and question-
naires filled in by participants. Exclusion criteria were nursing
home residency, hospital or psychiatric institute admission,
severe cognitive limitations (as diagnosed by the patients’ GP)
and comorbidities that have a major negative effect on
mobility: a history of myocardial infarction <6 months prior
to the start of the study, dyspnea or angina pectoris (New York
Heart Association (NYHA) class III or IV), any cerebrovascularaccident with residual motor symptoms, Parkinson’s disease,
corrected vision less than 0.5 (assessed with an eye chart), any
surgical procedure <3 months prior the start of the study,
presence of rheumatologic disease, active foot ulcer, any
amputation exceeding toes and the presence of limited
mobility. Limited mobility was assessed by asking persons
to report difficulty (none, a little, some, much difficulty or
inability) in walking (400 m) and climbing stairs (ten steps) as
described by Gregg et al. [4]. Limited mobility was defined as
much difficulty or inability to perform either task.
The study was approved by the local ethics committee of
the Maastricht University Medical Centre and all participants
gave written informed consent.
2.2. Assessment of diabetic complications and
related pathology
Peripheral neuropathy was classified according to the Clinical
Neurological Examination (CNE) score in which a score 5
indicates the presence of peripheral neuropathy [6]. In short,
the CNE score is determined by examining the Achilles tendon
reflex, vibration awareness, sharp–blunt discrimination,
touch sense, position sense of the hallux and manual
assessment of extensor muscle strength of the hallux and
flexor muscle strength of the foot in which all items are scored
as either normal, impaired or absent (0–2 points). In addition,
the scoring of light touch sense was related to the anatomical
level below which it is impaired (toe, mid-foot, ankle, mid-calf
and knee) (0–5 points). The presence of neuropathic pain was
assessed by the DN-4 questionnaire [7].
Intermittent Claudication (IC) was evaluated using the San
Diego Claudication Questionnaire [8]. The Ankle Brachial
Index (ABI) was measured with a hand-held doppler device
and a sphygmomanometer according to international stan-
dards [9]. Participants were classified as having peripheral
arterial disease (PAD) if the ABI was<0.90 or in the presence of
IC. Cardiovascular disease (CVD) was defined as a history of
stroke, transient ischemic attack, acute myocardial infarction,
angina pectoris and/or heart failure.
Hand grip strength was used as a measure of muscle
strength [10] and was measured three times, both at the right
and the left side, according to the recommendations of the
American Society of Hand Therapists [11] using a Jamar
dynamometer (Sammons Preston Inc., Bollingbrook, IL, USA).
The sex specific 20th percentiles were used as cut-off points
representing the presence of decreased muscle strength.
The seven item depression subscale of the Hospital Anxiety
and Depression Scale questionnaire was used to screen for
symptoms of depression [12]. The presence of mild or severe
symptoms of depression was determined using an eight point
cut-off [12].
2.3. Assessment of functional capacity and daily
walking activity
The timed ‘‘up and go’’ test (TUGT), the stair climbing test
(time needed to walk up and down 8 flights of stairs without
using the handrail) and the 6 Minutes Walk Test (6MWT) were
used as measures of functional capacity [13]. The 6MWT
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hard surface in a period of 6 min.
Physical activity was determined by two methods: a piezo-
electric pedometer (the New Lifestyle 2000 pedometer, New
lifestyles Inc., Lee’s Summit, MO, USA) to measure daily
walking activity and the PASE (Physical Activity Scale for the
Elderly) questionnaire to evaluate the frequency of different
physical activities (e.g. walking or cycling) [14].
The pedometer was clipped to the clothing of the
participant in a horizontal position at the waist, half way
between the belly button and hip. All participants were
instructed to wear the pedometer constantly for seven days
from the moment they got up until they went to bed, except
while bathing, and were encouraged to maintain their normal
routine. In addition, participants were instructed to report, in a
diary, the time of awakening, bedtime, and the hours and
reason for not wearing the pedometer. Participants were
blinded to the daily step count and after the seven day period
the pedometer was collected at the participants’ home. Mean
daily step count was calculated by averaging daily step counts
over the 7-day study period.
To test the accuracy of the pedometer a tri-axial acceler-
ometer (Dynaport Minimod, McRoberts, The Hague, the
Netherlands; range 2 g, sample frequency 100 Hz), attached
to the dorsal side of the lower trunk, was used. During the
6MWT we compared, in all participants, steps counted by the
accelerometer and the pedometer. Accelerometer data was
analysed for step detection according to the method described
by Zijlstra and Hof [15]. To compare steps counted by the
pedometer and the accelerometer during the 6MWT, the[()TD$FIG]
Fig. 1 – Flow chart ofPearson correlation coefficient was calculated and a Bland–
Altman plot was computed.
2.4. Other measurements
A questionnaire was used to obtain information about highest
level of education, employment status, visual impairment,
diabetes duration and treatment, use of antihypertensive
medication, frequency of falls during the past year and fear of
falling during walking. A fall was defined as an unexpected
change in position in which a person lands on the floor or
ground. Recent (3 months) HbA1c levels were extracted from
patient records. Height, weight and waist circumference were
measured according to international standards.
2.5. Statistical analysis
All analyses were executed with SPSS (SPSS, Chicago, IL, USA).
For all analyses assumptions of parametric tests were
evaluated. If necessary, log transformations were applied.
We used linear regression analyses (univariate and multivari-
ate) to identify determinants of daily walking activity (steps/
day). Because mobility in persons with type 2 diabetes is
believed to be impaired by peripheral neuropathy, PAD and
muscle strength [4,16–18], these parameters were added first
in regression analyses (enter method). We then used forward
analyses to evaluate whether the following determinants had
a significant contribution to this model: BMI, waist circumfer-
ence (analysed as a dichotomous variable using a cut-off
point of 88.0 cm for women and 102.0 cm for men), CVD,selection process.
Table 1 – Study population characteristics.
n = 100
Age (years) 64.5  9.4
Sex (% male/female) 69.0/31.0
Employment status (% employed) 26.0
Education (% highest education
primary school or less)
25.0
Diabetes duration (years) (median, IQR) 4.0 (2.0–7.0)
Treatment
- Diet with or without oral hypoglycemic
agents (%)
86.0
- Insulin (%) 14.0
BMI (kg/m2) 30.8  4.6
BMI < 25 kg/m2 (%) 7.0
BMI  25 kg/m2 and <30 kg/m2 (%) 40.0
BMI  30 kg/m2 (%) 53.0
Waist circumference (cm)
Male 109.6  11.7
Female 97.8  12.8
Blood pressure (mmHg)
- Systolic pressure 146  16
- Diastolic pressure 83  8
Use of antihypertensive medication (%) 69.0
HbA1c (%) 6.8  0.8
PAD (%) 14.5
CVD (%) 23.0
Peripheral neuropathy (%) 40.0
Neuropathic pain (%) 16.0
Hand grip strength (kg)
- Men 43.4  9.7
- Women 26.1  4.9
Mild-severe depressive symptoms (%) 17.0
Falls (% reporting  one fall in previous year) 10.0
Fear of falling (%) 24.0
Data are means  SD unless otherwise stated. Abbreviations:
IQR = interquartile range, BMI = body mass index, PAD = peripheral
arterial disease, CVD = cardiovascular disease.
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fall vs. no fall in the previous year) and fear of falling during
walking. The 6MWT, the TUGT and the stair climbing test are
commonly used as measures of functional capacity. Diabetic
complications and underlying pathology could affect daily
physical activity by reducing functional capacity. Therefore,
we analysed the correlation between the aforementioned
functional capacity tests and walking. In addition, multiple
regression analyses were performed to investigate whether
the determinants of functional capacity are similar to the
determinants of walking. Peripheral neuropathy, PAD and
decreased muscle strength were added first in these
regression analyses, because, as described above, these
factors are believed to impair mobility and in the forward
analyses the same determinants were added as in the
analyses described above. All multivariate analyses were




Of the random sample of 400 patients, 122 persons were
excluded, 11 persons could not be contacted by phone and
mail and 162 persons refused to participate (Fig. 1). Persons
refusing to participate were evenly distributed over the ten
participating practices, but were on average older (68.6  10.9
years) and more often female (54%) compared to persons in the
study population (p < 0.05). Five participants were excluded
after study participation because they suffered from an acute
illness interfering with normal activities during the week of
pedometer wear. The final sample thus consisted of 100
participants. Table 1 shows the study population character-
istics.
3.2. Functional capacity
The mean distance walked during the 6MWT was 537  89 m,
the mean time used to perform the TUGT was 8.3  1.8 s, and
the median [interquartile range, IQR] time to walk up and
down 8 flights of stairs was 7.9 [8.3–12.6] s. Multiple regression
analyses revealed that decreased muscle strength, PAD and
BMI were significantly associated with the distance walked
during the 6MWT (Table 2A). In the final regression model of
the TUGT, decreased muscle strength and BMI were signifi-
cantly associated with time needed to perform the test (Table
2B) and decreased muscle strength, BMI and fear of falling
were significantly associated with the logarithm of time
needed to perform the stair climbing test (Table 2C). In
contrast, peripheral neuropathy, although associated with a
marked reduction in walking activity as described below, was
not significantly associated with any of these tests.
3.3. Daily walking activity
As evaluated with PASE questionnaire, brisk walking was the
most frequently reported physical activity (41% of all
participants reported brisk walking). Other frequentlyreported activities were cycling (28%) and fitness training
(14%). Out of a 700 person-days of pedometer wear, 676 days
were available for the present analyses as on 24 days
participants forgot to wear the pedometer (self-reported wear
time). Mean time of pedometer wear was 14.9  1.1 h/day. The
median [IQR] of steps/day was: 6429 [4517–8573]. The correla-
tion coefficient between steps counted by the pedometer and
the accelerometer was 0.96 (p < 0.001). The Bland–Altman plot
showed that the difference of steps counted by both devices
was within 2% of mean steps counted, except for five
participants (plot not shown). The reason for the large
deviation (between 5% and 13% of mean steps counted) in
these five participants could not be determined. The correla-
tion between physical activity as measured with the PASE
questionnaire and the number of steps/day was low, r = 0.30
(p < 0.05). The correlation coefficient between the 6MWT and
walking activity was 0.37 ( p < 0.001), between the TGUT and
walking activity 0.37 ( p < 0.001) and between stair climbing
and walking activity 0.36 (p < 0.001).
3.4. Determinants of walking
In univariate regression analyses, daily walking activity
decreased significantly with BMI, waist circumference, pe-
Table 2 – Final model regression analysis with diabetic complications and underlying pathology as determinants of
6MWT, TUGT, stair climbing test and steps/day.
Determinant Unstandardized b (95% CI)a,b p-Value
(A) 6MWT
PAD vs. no PAD 69.3 (104.9; 34.2) <0.005
Peripheral neuropathy vs. no neuropathy 30.4 (63.2; 2.5) 0.07
Decreased muscle strength vs. no decreased muscle strength 69.6 (104.9; 34.2) <0.001
BMI 5.4 (8.3; 2.5) <0.005
(B) TUGT
PAD vs. no PAD 0.40 (0.50; 1.30) 0.38
Peripheral neuropathy vs. no neuropathy 0.46 (0.19; 1,11) 0.17
Decreased muscle strength vs. no decreased muscle strength 1.52 (0.82; 2.22) <0.001
Fear of falling vs. no fear of falling 0.61 (0.07; 1.30) 0.08
BMI 0.09 (0.04; 0.15) <0.005
(C) Stair climbingc
PAD vs. no PAD 0.03 (0.03; 0.09) 0.35
Peripheral neuropathy vs. no neuropathy 0.01 (0.03; 0.05) 0.54
Decreased muscle strength vs. no decreased muscle strength 0.10 (0.05; 0.14) <0.001
Fear of falling vs. no fear of falling 0.05 (0.02; 0.09) <0.05
BMI 0.01 (0.002; 0.10) <0.005
(D) Steps/day
PAD vs. no PAD 1453 (3387; 481) 0.14
Peripheral neuropathy vs. no neuropathy 1967 (3421; 513) <0.05
Decreased muscle strength vs. no decreased muscle strength 1782 (3348; 217) <0.05
BMI 210 (337; 83) <0.005
R2 model A = 0.51, R2 model B = 0.53, R2 model C = 0.65, R2 model D = 0.30. Abbreviations: 6MWT = 6 min walk test, PAD = peripheral arterial
disease, BMI = body mass index, TUGT = timed ‘‘up and go’’ test.
a Data are adjusted for age and sex.
b Data are presented unadjusted for mean time of pedometer wear.
c Data are log transformed.
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(Table 3). In the final regression model, which included PAD,
peripheral neuropathy, decreased muscle strength and BMI,
and which was adjusted for age and sex, persons with
peripheral neuropathy took 1967 (95% CI 3421 to 513,
p < 0.05) steps/day less than persons without peripheral
neuropathy, persons with decreased muscle strength took
1782 (3348 to 217, p < 0.05) steps/day less than persons







PAD vs. no PAD
CVD vs. no CVD
Peripheral neuropathy vs. no neuropathy
Neuropathic pain vs. no neuropathic pain
Reduced muscle strength vs. no Decreased muscle strength
Symptoms of depression vs. no symptoms of depression
Fall(s) vs. no fall in previous year
Fear of falling vs. no fear of falling
Abbreviations: BMI = body mass index, PAD = peripheral arterial disease
a Data are presented unadjusted for mean time of pedometer wear.
b The relationship between these determinants and steps/day is express1 kg/m2 was associated with a decrease in steps of 210 (337 to
83, p < 0.005) per day (Table 2D). Adjusting the number of
steps per day for mean time of pedometer wear did not affect
the outcome of either univariate or multivariate analyses (data
not shown). We evaluated whether factors, other than diabetic
complications and underlying pathology, are associated with
physical activity. These analyses showed that age and the use
of antihypertensive medication were significantly associated
with steps/day (Table 4).underlying pathology as possible determinants of steps/
Standardized b (95% CI)a,b p-Value
0.21 (0.41; 0.01) <0.05
0.42 (0.71; 0.14) <0.05
0.01 (0.37; 0.34) 0.94
0.23 (0.45; 0.01) <0.05
0.16 (0.35; 0.04) 0.12
0.39 (0.58; 0.21) <0.001
0.04 (0.24; 0.17) 0.72
0.30 (0.50; 0.11) <0.005
0.04 (0.24; 0.16) 0.70
0.08 (0.28; 0.13) 0.46
0.16 (0.36; 0.04) 0.11
, CVD = cardiovascular disease.
ed as standardized regression coefficients (standardized b).
Table 4 – Univariate analyses of factors other than diabetic complications and underlying pathology as possible
determinants of steps/day.
Determinant Standardized b (95% CI)a,b p-Value
Male vs. female 0.02 (0.22; 0.18) 0.87
Age 0.32 (0.51; 0.13) <0.005
Unemployed vs. employed 0.17 (0.37; 0.03) 0.09
Education primary school or less vs. >primary school 0.12 (0.32; 0.08) 0.25
Insulin vs. diet with or without oral hypoglycemic agents 0.17 (0.37; 0.03) 0.09
Diabetes duration 0.11 (0.09; 0.31) 0.26
Blood pressure
- Systolic pressure 0.001 (0.20; 0.20) 0.99
- Diastolic pressure 0.15 (0.05; 0.35) 0.14
Antihypertensive medication vs. no antihypertensive medications 0.24 (0.43; 0.04) <0.05
HbA1c 0.08 (0.29; 0.12) 0.42
LDL cholesterol 0.10 (0.12; 0.31) 0.38
HDL cholesterol 0.15 (0.06; 0.37) 0.16
Triglycerides 0.01 (0.21; 0.22) 0.95
a Data are presented unadjusted for mean time of pedometer wear.
b The relationship between these determinants and steps/day is expressed as standardized regression coefficients (standardized b).
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The aim of this study was to investigate the associations of
diabetic complications and underlying pathology with daily
walking activity in persons with type 2 diabetes without
manifest mobility limitations. A population of persons with
type 2 diabetes treated in primary care was selected with a
mean age of 64.5 years, a relatively short diabetes duration
(median 4 years) and good glycemic control (mean HbA1c
6.8%). However, the prevalence of in particular peripheral
neuropathy (40%) and obesity (BMI > 30 kg/m2; 53%) was high.
Using an accurate pedometer, we found that diabetic
persons took around 6500 steps/day, which is clearly below the
recommended level of 10,000 steps/day [19]. Peripheral
neuropathy and decreased muscle strength were associated
with a marked reduction of walking activity (approximately
1950 and 1800 steps/day), and a 1 kg/m2 increase in BMI was
associated with a decrease in steps of around 200 per day. The
association between three commonly used tests to measure
functional capacity (brisk walking, stair climbing and standing
up from chair) and walking activity was relatively low.
Decreased muscle strength and obesity were associated with
a decrease in functional capacity in these three different tests.
However, peripheral neuropathy, although strongly associat-
ed with walking, was not associated with decreased functional
capacity.
Innovative aspects of this study are the use of a validated
pedometer to assess walking activity continuously during 7
days and the determination of the effect of several diabetes-
related pathologies on daily activity in a relatively healthy
population of diabetic subjects. Although this study gives new
insights into the causes of physical inactivity in daily life in
type 2 diabetes, it has several limitations. Firstly, some
potential determinants of physical activity were not assessed,
including arthritis, diastolic dysfunction and cognitive impair-
ments. In addition, we did not measure other possible
determinants than diabetic complications or underlying
pathologies, such as sociodemographic, motivational and
environmental factors. This may explain the low R2 value of0.30 in our model of determinants of daily walking activity, i.e.
a large part of the variability in daily step count is explained by
other factors than the ones included in the model (age, sex,
peripheral neuropathy, decreased muscle strength, BMI and
PAD). Secondly, the study has a limited sample size. Thirdly,
muscle strength was measured as hand grip strength, but we
did not assess muscle strength of the legs. Finally, the results
of this study cannot be generalized to diabetic patients with
mobility limitations, as the aim of this study was to evaluate
physical activity in persons without manifest mobility
limitations.
The inexpensive and easily to administered pedometer is
an attractive method to study walking activity in persons with
diabetes. Previous research showed that walking is the
physical activity most frequently engaged by persons with
type 2 diabetes [2], which we also observed in our patients.
Earlier studies showed convergent and construct validity of
pedometers to assess physical activity [20,21]. In this study,
the pedometer correlated moderately with the PASE ques-
tionnaire. Previous research found comparable results [20].
However, to our knowledge, pedometers have not been
validated in persons with type 2 diabetes. Gait disorders,
obesity and slow walking speed, all more prevalent in persons
with diabetes, can affect the accuracy of the pedometer [22].
Therefore, we evaluated the accuracy of this device using a tri-
axial accelerometer. An tri-axial accelerometer is accurate in
detecting steps [15,23]. This study showed that the New
Lifestyle 2000 pedometer is as accurate as the accelerometer in
detecting steps under laboratory conditions in persons with
type 2 diabetes without manifest mobility limitations. Parti-
cipants took around 6500 steps/day; recently proposed indices
consider 6500 steps/day as ‘low active’ [24]. Tudor-Locke et al.
reported that the mean steps/day was 6662 in a sample of 160
persons with type 2 diabetes living in the USA [19], which is
comparable to the 6500 steps/day found in our sample.
Because of the cross-sectional design of this study no direct
inferences can be made about the causal relationship between
the determinants found and walking. However, loss of walking
activity is most likely both the cause and the consequence of
the determinants found. In this concept, there is a negative
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tions, which in turn affect physical activity. Physical inactivity
results in reduced muscle strength, increased weight and
worse glycemic control, culminating in a higher risk of diabetic
complications [1]. On the other hand, the determinants found
are themselves probably also a cause of physical inactivity.
Although peripheral neuropathy and its associated loss in
peripheral sensation have been well described in the
literature, only in recent years attention has been paid to
the effects of peripheral neuropathy on mobility. It has
become apparent that peripheral neuropathy is associated
with reduced muscle strength, decrements in balance, gait
abnormalities and an increased risk of falling, all of which
affect the ability to be physically active [18]. Also decreased
muscle strength and obesity have been associated with
limited mobility [16] and in our patients decreased muscle
strength was associated with a reduction in both functional
capacity and daily walking activity, independent of the
presence neuropathy. Persons with type 2 diabetes have
both lower muscle strength and muscle quality (defined as
the ratio of strength to the corresponding muscle mass in
kilograms) compared to persons without diabetes [17].
Factors contributing to this are, next to peripheral neuropa-
thy and physical inactivity, possibly a direct effect of
hyperglycemia, (subclinical) PAD, and the presence of high
levels of inflammatory cytokines.
Peripheral neuropathy was associated with a marked
reduction in daily walking activity, however it was, in contrast
to BMI and decreased muscle strength, not associated with
outcome of functional capacity tests. A possible explanation is
that peripheral neuropathy only affects mobility in challeng-
ing environments (i.e. in daily life) and not under ideal,
standard conditions (i.e. walking on a flat, regular surface as
during the 6MWT). This is in accordance with previous gait
analysis studies. Menz et al. [25] showed that step-time
variability, which has been associated with falls [25], only
differed between diabetic persons with peripheral neuropathy
and healthy controls if walking on a irregular surface and not
on a level surface. In accordance, Allet et al. [26] showed that
when changing the walking surface from tar to stones, gait
parameters deteriorate more markedly in diabetic persons
with peripheral neuropathy. However, some studies did find a
relationship between peripheral neuropathy and mobility
limitations under ideal, standard conditions [18,27] and this
topic needs further research.
In conclusion, this study demonstrates that in persons with
type 2 diabetes without manifest mobility limitations, periph-
eral neuropathy, decreased muscle strength and obesity are
strongly associated with loss of walking activity. This suggests
that a great number of persons with diabetes are affected in
their capacity to be physically active because of the presence
of diabetes-related pathologies. More research is needed to
evaluate whether failure to recognise these disorders is one of
the factors explaining the low success rate of exercise
intervention programmes in diabetes.
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